GBP6抗体;GBP6 Antibody—艾普蒂 新品

+ +

•  

   

     Western blot analysis using GBP6 mouse mAb against  tonsil tissue lysate    

  
  

•  

   

     Lane 1: Tonsil tissue lysate ;  Lane 2: GBP6 immunoprecipitated from tonsil tissue lysate by P15022;  Lane 3: The same as Lane 2 but use IgG isotype control antibody ;Result: P15022 can immunoprecipitate GBP6;    

  
  

•  

   

     IHC-P analysis of esophagus tissue by GBP6 antibody (P15022) IHC-P was performed using sections of the formalin-fixed paraffin-embedded esophagus tissue;Result: Squamous epithelial cells are positively stained at the cytoplasm.    

  
  

**Background of GBP6 Antibody**

The Guanylate-Binding Protein 6 (GBP6) antibody is a research tool designed to detect and study GBP6. a member of the guanylate-binding protein family. GBPs are interferon-inducible GTPases that play critical roles in innate immunity, particularly in host defense against intracellular pathogens such as bacteria, viruses, and parasites. GBP6. though less characterized than other family members (e.g., GBP1 or GBP5), is hypothesized to contribute to immune responses by disrupting pathogen membranes or regulating inflammatory signaling pathways.

GBP6 expression is primarily induced by type II interferon (IFN-γ) and is associated with immune cells, including macrophages and T cells. Its function may involve coordinating antimicrobial activity or modulating autophagy. The GBP6 antibody enables researchers to investigate its expression patterns, subcellular localization, and interactions in immune-related contexts.

Studies using GBP6 antibodies have explored its role in diseases such as viral infections, autoimmune disorders, and cancers, where dysregulated GBP expression may influence disease progression. Available as monoclonal or polyclonal versions, these antibodies are validated for techniques like Western blotting, immunohistochemistry, and immunofluorescence. Ongoing research aims to clarify GBP6's precise mechanistic contributions, potentially revealing therapeutic targets for immune-mediated conditions.